Does MPL have a patent for MPL-TL?
Molecular Pharmacology Limited, in cooperation with its scientific partner, announced in February 2005 that it had lodged completed patent specification in the USA and provisional specification in Australia for its propriety analgesic and anti-inflammatory compound, MPL-TL. The lodgement of a US Specification in Completion allows the company to seek examination in the USA earlier than would otherwise be the case. The patents seek to provide broad and early protection for the company’s analgesic and anti-inflammatory intellectual property. The parallel lodgement in Australia provides the company with a single priority date in both the USA and PCT countries. The company has adopted this two-part patent strategy to support its international market potential.
